The first British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS)-endorsed faecal microbiota transplant (FMT) guidelines were published in 2018. Over the past 5 years, there has been considerable growth in the evidence base (including publication of outcomes from large national FMT registries), necessitating an updated critical review of the literature and a second edition of the BSG/HIS FMT guidelines. These have been produced in accordance with National Institute for Health and Care Excellence-accredited methodology, thus have particular relevance for UK-based clinicians, but are intended to be of pertinence internationally. This second edition of the guidelines have been divided into recommendations, good practice points and recommendations against certain practices. With respect to FMT for infection (CDI), key focus areas centred around timing of administration, increasing clinical experience of encapsulated FMT preparations and optimising donor screening. The latter topic is of particular relevance given the COVID-19 pandemic, and cases of patient morbidity and mortality resulting from FMT-related pathogen transmission. The guidelines also considered emergent literature on the use of FMT in non-CDI settings (including both gastrointestinal and non-gastrointestinal indications), reviewing relevant randomised controlled trials. Recommendations are provided regarding special areas (including compassionate FMT use), and considerations regarding the evolving landscape of FMT and microbiome therapeutics.

中文翻译：

---

使用粪便微生物移植治疗复发性或难治性艰难梭菌感染和其他潜在适应症：英国胃肠病学会 (BSG) 和医疗保健感染学会 (HIS) 联合指南第二版

第一份英国胃肠病学会 (BSG) 和医疗保健感染学会 (HIS) 认可的粪便微生物群移植 (FMT) 指南于 2018 年发布。在过去 5 年里，证据基础有了相当大的增长（包括结果的发布）来自大型国家 FMT 登记处），需要对文献进行更新的批判性审查以及 BSG/HIS FMT 指南的第二版。这些是根据国家健康与护理卓越研究所认可的方法制作的，因此与英国的临床医生特别相关，但旨在在国际上具有相关性。第二版指南分为建议、良好实践要点和针对某些实践的建议。对于感染 FMT (CDI)，关键重点领域集中在给药时机、增加胶囊化 FMT 制剂的临床经验以及优化供体筛选。考虑到 COVID-19 大流行以及 FMT 相关病原体传播导致的患者发病率和死亡率，后一个主题尤其重要。该指南还考虑了关于在非 CDI 环境（包括胃肠道和非胃肠道适应症）中使用 FMT 的新兴文献，回顾了相关的随机对照试验。提供了有关特殊领域（包括富有同情心的 FMT 使用）的建议，以及有关 FMT 和微生物组疗法不断发展的前景的考虑因素。